Clinical Trial Identifier: NCT06732180
Status: Recruiting
Sponsor: Gain Therapeutics, Inc.
Phase: Phase 1
Intervention: GT-02287 (oral, once daily)
Trial Overview
This Phase 1 clinical trial evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics of GT-02287 in patients with Parkinson's Disease.
Study Design
Trial Type: Single-arm (all participants receive active molecule)
GT-02287 is a novel protein stabilizer being developed for Parkinson's Disease. The compound targets protein misfolding, a key pathological feature in neurodegenerative diseases. By stabilizing native protein conformations, GT-02287 may help protect neurons from toxic aggregation.
Gain Therapeutics uses a proprietary computer-aided drug design platform to identify allosteric binding sites and develop small molecules that stabilize properly folded proteins. This approach differs from traditional enzyme inhibitors and aims to address the root cause of protein misfolding in PD.
Clinical Rationale
Protein misfolding and aggregation are central to Parkinson's disease pathogenesis, particularly involving alpha-synuclein[@alphasyn2023]. GT-02287 represents a novel mechanism targeting the upstream process of protein aggregation rather than downstream symptoms.
Protein Stabilization Approach
Traditional vs. Stabilization Approach
...
Clinical Trial Identifier: NCT06732180
Status: Recruiting
Sponsor: Gain Therapeutics, Inc.
Phase: Phase 1
Intervention: GT-02287 (oral, once daily)
Trial Overview
This Phase 1 clinical trial evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics of GT-02287 in patients with Parkinson's Disease.
Study Design
Trial Type: Single-arm (all participants receive active molecule)
GT-02287 is a novel protein stabilizer being developed for Parkinson's Disease. The compound targets protein misfolding, a key pathological feature in neurodegenerative diseases. By stabilizing native protein conformations, GT-02287 may help protect neurons from toxic aggregation.
Gain Therapeutics uses a proprietary computer-aided drug design platform to identify allosteric binding sites and develop small molecules that stabilize properly folded proteins. This approach differs from traditional enzyme inhibitors and aims to address the root cause of protein misfolding in PD.
Clinical Rationale
Protein misfolding and aggregation are central to Parkinson's disease pathogenesis, particularly involving alpha-synuclein[@alphasyn2023]. GT-02287 represents a novel mechanism targeting the upstream process of protein aggregation rather than downstream symptoms.
Protein Stabilization Approach
Traditional vs. Stabilization Approach
Most drug development targets enzyme active sites or receptors. The protein stabilization approach by Gain Therapeutics takes a fundamentally different strategy[@proteinmisfold2024]:
| Approach | Target | Example | |----------|--------|---------| | Enzyme inhibition | Active site | MAO-B inhibitors | | Receptor agonism/antagonism | Binding site | Dopamine agonists | | Protein stabilization | Allosteric sites | GT-02287 |
Platform Technology
Gain Therapeutics uses a proprietary platform combining:
Computational modeling: Identification of allosteric binding sites
Site-Targeted Affinity Transition (STAT): Algorithm for identifying stabilizers
Machine learning: Optimizing drug-like properties
This approach has identified novel binding sites not visible through traditional methods, enabling development of molecules that stabilize protein conformation.
Mechanism in Parkinson's Disease
Alpha-Synuclein Pathology
In PD, the protein [alpha-synuclein](/proteins/alpha-synuclein) undergoes:
Misfolding: Normal soluble protein adopts abnormal conformation
Oligomerization: Forms toxic soluble oligomers
Aggregation: Forms insoluble fibrils (Lewy bodies)
Propagation: Spreads between neurons via prion-like mechanism
GT-02287 Action
GT-02287 acts by:
Binding: Identifies specific allosteric site on target protein
Stabilization: Locks protein in native, functional conformation
Prevention: Reduces misfolding and subsequent aggregation
Disease-modifying: Targets root cause of protein misfolding
Broad applicability: Platform applicable to multiple neurodegenerative diseases
Expected Outcomes
Primary endpoints include safety and tolerability assessments. Pharmacokinetic and pharmacodynamic markers will characterize drug exposure and biological effects in blood and cerebrospinal fluid[@gainthera2024].
[alpha-synuclein](/proteins/alpha-synuclein) - target of protein stabilization therapy
[Protein Misfolding in Neurodegeneration](/mechanisms/protein-misfolding-neurodegeneration)
[Small Molecule Therapies for PD](/therapeutics/small-molecule-parkinsons)
References
[NCT06732180 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease](https://clinicaltrials.gov/study/NCT06732180)
[GT-02287: A novel protein stabilizer for Parkinson's disease (2024)](https://doi.org/10.3233/JPD-240123)
[Protein misfolding in neurodegenerative diseases: mechanisms and therapeutic targets (2024)](https://doi.org/10.1038/s41573-024-00876-5)
[Alpha-synuclein structure, function, and dysfunction in Parkinson's disease (2023)](https://doi.org/10.1016/j.neuron.2023.05.001)